It can lead to unsafe self-adjusting People take more one week, less the next, trying to find the sweet spot. This increases risk, not safety
In research discussions, Mounjaro is usually described in relation to GLP-1 and GIP receptor pathways
GLP-1 drugs, short for glucagon-like peptide-1, were developed to manage type 2 diabetes but have gained cultural cachet for their appetite-suppressing, weight-loss effects
Some use it for fitness, while others focus on anti-aging or recovery
Calling it GLP-3 may be convenient for search and marketing, but it is less precise
Eli Lilly has already signaled its supply readiness by building a $1.5 billion inventory of orforglipron ahead of the anticipated FDA decision, a level of pre-approval investment that reflects confidence in both the approval and the commercial potential of the product